Q2 2025 ContextVision AB Earnings Call Transcript
Key Points
- ContextVision AB (LTS:0L8Z) expanded its partnership network by signing agreements with University of Waterloo, InPhase Solutions, and AMRA Medical, enhancing its capabilities in quantitative ultrasound and AI-based solutions.
- The company released a major upgrade for its Rivent software and completed a new software platform, setting the foundation for a series of clinically focused products.
- Despite a challenging market, ContextVision AB (LTS:0L8Z) maintained a strong cash position of SEK70 million, providing ample headroom for future investments and shareholder value activities.
- The company reported a compounded average growth rate of 8.4% between 2020 and 2024, indicating a stable long-term growth trajectory.
- ContextVision AB (LTS:0L8Z) is progressing well in its Data Quality segment, with steady progress on milestones and a focus on developing solutions for fatty liver disease, a prevalent and fast-growing chronic condition.
- The company experienced a 10% decline in revenue compared to the previous year, with revenues reaching SEK28.6 million in the second quarter of 2025.
- ContextVision AB (LTS:0L8Z) faced FX headwinds, with the weakening of the US dollar and euro against the SEK negatively impacting revenue by 3.5%.
- There was a decrease in license sales in Asia due to uncertain market conditions, contributing to the overall revenue decline.
- The company lost a particular X-ray platform to a low-priced competitor in Asia and is facing the phaseout of an ultrasound platform, affecting short-term performance.
- Global trade and supply chain issues are causing delays in purchasing decisions, creating an unpredictable market environment that may persist in the near term.
Welcome to ContextVision, and welcome to the presentation of our second quarter results. Today with Richard, our CFO; myself, Gerald, we have an agenda with three agenda items, a business update, a deep dive into the financial development and a brief summary and outlook.
Without further ado, let's look into the business update and the second quarter 2025. We continue to expand our partnership network to advance into quantitative ultrasound. And in the second quarter, we have signed up University of Waterloo, InPhase Solutions and AMRA Medical. We have attended a conference, CMEF, in Shanghai in April. We have signed up a new customer and a new platform also in Asia, and that was within Specialty ultrasound.
And I'm very excited that we have released in the second quarter a major Rivent upgrade as well as a completion of an entirely new software platform with a new architecture that will be the foundation for an entire new series of products that are going to be clinically focused.
Now looking at the financials. We saw
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
